NovoCure Limited (NVCR)

Market Cap	2.08B +7.0%
Revenue (ttm)	674.41M +8.5%
Net Income	-173.05M
EPS	-1.54
Shares Out	115.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	848,886
Open	17.98
Previous Close	17.96
Day's Range	17.78 - 18.17
52-Week Range	9.82 - 20.06
Beta	0.90
Analysts	Buy
Price Target	26.29 (+46.38%)
Earnings Date	Apr 30, 2026

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,605
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $26.29, which is an increase of 46.38% from the latest price.

Price Target

$26.29

(46.38% upside)

Analyst Consensus: Buy